Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on December 5, 2025, covering events occurring on December 1, 2025, and December 5, 2025. The Company is a biopharmaceutical firm focused on developing therapies for neurodegenerative diseases and other conditions.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a Current Report (Form 8-K) focused on specific corporate events rather than a periodic financial statement (10-K or 10-Q).
Material Changes and Events
- Phase 2 MINDFuL Trial Data: On December 1, 2025, the Company announced new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer's disease and elevated neuroinflammation.
- CORDStrom Platform Publication: On December 5, 2025, the Company announced a recently published overview regarding future applications and research areas for mesenchymal stromal cell therapies, specifically highlighting its CORDStrom platform.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future financial performance, or specific risk factors beyond the general nature of clinical trial data announcements. The primary focus is on the dissemination of scientific data and research overviews.
Investor Verification Checklist
- Review the full text of the press release attached as Exhibit 99.1 for specific details on the neuroimaging data from the MINDFuL trial.
- Examine the publication referenced in Exhibit 99.2 to understand the scope of the CORDStrom platform's future applications.
- Verify the Company's cash position and runway in the most recent 10-Q or 10-K, as this 8-K does not contain financial statements.